Review Article
COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!

https://doi.org/10.1016/j.jceh.2020.06.003Get rights and content

The coronavirus disease 2019 (COVID-19) has turned into a global human tragedy and economic devastation. Governments have implemented lockdown measures, blocked international travel, and enforced other public containment measures to mitigate the virus morbidity and mortality. As of today, no drug has the power to fight the infection and bring normalcy to the utter chaos. This leaves us with only one choice namely an effective and safe vaccine that shall be manufactured as soon as possible and available to all countries and populations affected by the pandemic at an affordable price. There has been an unprecedented fast track path taken in Research & Development by the World community for developing an effective and safe vaccine. Platform technology has been exploited to develop candidate vaccines in a matter of days to weeks, and as of now, 108 such vaccines are available. Six of these vaccines have entered clinical trials. As clinical trials are “rate-limiting” and “time-consuming”, many innovative methods are in practice for a fast track. These include parallel phase I-II trials and obtaining efficacy data from phase IIb trials. Human “challenge experiments” to confirm efficacy in humans is under serious consideration. The availability of the COVID-19 vaccine has become a race against time in the middle of death and devastation. There is an atmosphere of tremendous hype around the COVID-19 vaccine, and developers are using every moment to make claims, which remain unverified. However, concerns are raised about a rush to deploy a COVID-19 vaccine. Applying “Quick fix” and “short cuts” can lead to errors with disastrous consequences.

Keywords

COVID-19
SARS-CoV-2
coronavirus
vaccine
platform technology clinical trials

Abbreviations

ADE
Antibody-Dependent Enhancement
CEPI
Coalition for Epidemic Preparedness Innovations
COVID-19
Coronavirus Disease 2019
MERS-CoV
Middle East Respiratory Syndrome Coronavirus
MHC
Major Histocompatibility Complex
SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus 2
WHO
World Health Organization

Cited by (0)

View Abstract